科研之友
微信
新浪微博
Facebook
分享链接
摘要
Multiple placebo-controlled trials have demonstrated that intravenous vernakalant, a novel antiarrhythmic agent, effectively converts recent-onset atrial fibrillation in similar to 50% of patients within 90 min of administration. Results from the AVRO trial corroborate these findings and further show that vernakalant is superior to amiodarone in the treatment of this condition.
- 出版日期2011-4
